Department of Development for New Drugs, School of Pharmacy, Hebei Medical University, Shijiazhuang 050017, China.
Eur J Med Chem. 2011 Mar;46(3):934-43. doi: 10.1016/j.ejmech.2011.01.010. Epub 2011 Jan 22.
Voltage-gated Kv7/KCNQ/M-potassium channels play a pivotal role in controlling neuronal excitability. Genetic reduction of KCNQ channel activity as a result of mutations causes various human diseases such as epilepsy and arrhythmia. Therefore, discovery of small molecules that activate KCNQ channels is an important strategy for clinical intervention of membrane excitability related disorders. In this study, a series of pyrazolo[1,5-a]pyrimidin-7(4H)-ones (PPOs) have been found to be novel activators (openers) of KCNQ2/3 potassium channels through high-throughput screening by using atomic absorption rubidium efflux assay. Based on structure-activity relationship (SAR), the substituted PPOs have been optimized. The 5-(2,6-dichloro-5-fluoropyridin-3-yl)-3-phenyl-2-(trifluoromethyl) pyrazolo[1,5-a]pyrimidin-7(4H)-one (17) was identified as a novel, potent, and selective KCNQ2/3 potassium channel opener by patch-clamp recording assay.
电压门控 Kv7/KCNQ/M-钾通道在控制神经元兴奋性方面起着关键作用。由于基因突变导致 KCNQ 通道活性降低,会引起各种人类疾病,如癫痫和心律失常。因此,发现能激活 KCNQ 通道的小分子是治疗与膜兴奋性相关的疾病的重要策略。在这项研究中,通过高通量筛选原子吸收铷外流测定法,发现一系列吡唑并[1,5-a]嘧啶-7(4H)-酮(PPO)是 KCNQ2/3 钾通道的新型激活剂(开放剂)。基于构效关系(SAR),对取代的 PPO 进行了优化。通过膜片钳记录分析,鉴定出 5-(2,6-二氯-5-氟吡啶-3-基)-3-苯基-2-(三氟甲基)吡唑并[1,5-a]嘧啶-7(4H)-酮(17)是一种新型、有效且选择性的 KCNQ2/3 钾通道开放剂。